Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, engages in the development and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide which is in a phase 3 clinical trial to treat Barth syndrome, a phase 2/3 clinical trial for the treatment of Duchenne cardiomyopathy, a phase 2a clinical trial to treat Friedrich’s ataxia, a phase 2 clinical trial for treatment of dry age-related macular degeneration, phase 2 clinical trial to treat hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. Its product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson’s, Alzheimer’s, Huntington’s, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was formerly known as Stealth Peptides International, Inc. and changed its name to Stealth BioTherapeutics Corp in June 2015. The company was founded in 2006 and is based in Camana Bay, Cayman Islands.